GLP-1s push health plan costs to 15-year high

Published Updated 4 Min Read

Woman holding multiple GLP-1 injection pens, weight loss and diabetes treatment concept.
Adobe Stock

  • Key Insight: The real reason health costs are rising is a structural shift driven by GLP-1s.
  • What’s at Stake: Employers face long-term affordability crises as millions of workers become eligible for expensive treatments.
  • Supporting Data: 18.3% rise in prescription drug costs for certain employer-sponsored health plans.
  • Source: Bullets generated by AI with editorial review

The growing popularity of expensive GLP-1 drugs is helping push employer-sponsored health plan costs to their fastest growth rate in 15 years for 2027, according to a new survey.

Jimmy Nesbitt
Reporter

Jimmy Nesbitt is a reporter at Employee Benefit News, where he covers the evolving landscape of workplace benefits, healthcare, retirement, financial wellness and related policy issues. His career … Read full bio


For reprint and licensing requests for this article, click here.


More From Employee Benefit News

Sign Up Form

Login Modal Form